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S U M M A R Y
Objective: To describe overall site-speciﬁc hospital-acquired infection (HAI) rates and to describe the
microbiological and antibiotic resistance proﬁles of infecting pathogens, together with their impact on
multidrug-resistant (MDR) bacteria-associated mortality.
Methods: We conducted a 5-year retrospective descriptive study of HAI in patients in the intensive care
unit (ICU) of a cancer center in Mexico from January 2007 to December 2011. The following information
was collected: patient characteristics and comorbidities, data related to the neoplasm and its treatment,
microbiology, and the resistance pattern of all isolates.
Results: During the study period, 1418 patients were admitted to the ICU; 134 of them developed
159 infections, with an incidence of 11.2/100 hospitalized patients and 32.2/per 1000 patient-days. Two
hundred sixty-six microorganisms were isolated. The overall prevalence of MDR-HAI was 39.5%. The
most frequent organisms were as follows: 54 (20%) Escherichia coli (94.4% of these were extended-
spectrum beta-lactamase producers), 32 (12%) Staphylococcus aureus (90.6% of these were methicillin-
resistant), 32 (12%) Enterococcus faecium (18.7% of these were vancomycin-resistant), and 20 (6%)
Acinetobacter baumannii (all were MDR). Among patients admitted to the ICU, 252 (17.8%) died. Death
was related to the HAI in 58 (23%) of these patients (p < 0.001) and 51 (88%) had a MDR organism
isolated (p = 0.05).
Conclusions: The emergence of MDR bacteria poses a difﬁcult task for physicians, who have limited
therapeutic options. Critically ill cancer patients admitted to the ICU are at major risk of a bacterial MDR-
HAI that will impact adversely on mortality.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hospital-acquired infections (HAI) have been recognized for
over a century as a critical problem affecting the quality of
healthcare, and they constitute a major source of adverse
healthcare outcomes.1,2 The emergence of multidrug-resistant
bacteria (MDRB) has become a public health problem, creating a
new burden on medical care in hospitals, particularly for patients
admitted to intensive care units (ICU).1 In critical care units, there
is extensive antimicrobial use, which imposes a selection pressure
and promotes the emergence of MDRB.1 In addition to this, ICU
patients have an increased risk of infection due to their underlying* Corresponding author.
E-mail address: patcornejo@yahoo.com (P. Cornejo-Jua´rez).
http://dx.doi.org/10.1016/j.ijid.2014.12.022
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).diseases or conditions, impaired immunity, and exposure to
multiple invasive devices (mechanical ventilation, central venous
catheters (CVC), and urinary tract catheters).1,3,4 The incidence of
ICU-HAI is 5–10-times higher than HAI rates in general wards.5 HAI
in the ICU has been associated with increased morbidity, mortality,
and costs.1,6,7
The aim of this study was to describe the incidence of HAI in an
oncology ICU and to describe the microbiological and antibiotic
resistance proﬁles of infecting pathogens, together with their
impact on MDRB-associated mortality.
2. Methods
The National Cancer Institute of Mexico (INCan), located in
Mexico City, is a 135-bed referral and teaching hospital for adult
patients with cancer, with an average 170 000 medical visits perciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 2
Demographic and clinical characteristics in intensive care unit
(ICU) patients with hospital-acquired infections (HAI) (2007–
2011)
Characteristic, n (%) Patients (N = 134)
Age, years, median (range) 50 (16–93)
Male 65 (48.5%)
Underlying oncological disease
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indwelling CVC placements, 34 000 chemotherapy infusion
sessions, and >3500 major surgery procedures are carried out.
Efforts have been made to improve the outcome of cancer patients
admitted to the six-bed medical and surgical ICU,8 including better
selection of patients and standardized care. Nonetheless, mortality
trends have increased over the past years, in parallel with an
increase in MDRB-HAI (Table 1).
We conducted a 5-year retrospective descriptive study of HAI in
patients in the ICU, from January 2007 to December 2011. Data
were obtained from ICU daily reports, infection control surveil-
lance forms, microbiology laboratory reports, and patient medical
charts. The following information was collected: patient char-
acteristics and comorbidities, data related to the neoplasm and its
treatment, microbiology, and the resistance pattern of all isolates.
The Sequential Organ Failure Assessment (SOFA) score9 at ICU
admission and at detection of the infection, length of ICU stay,
number of ventilator days, days of CVC placement, and urinary
tract catheter days were also reviewed. HAI was deﬁned using the
Centers for Disease Control and Prevention criteria (CDC, 2008).10
Cultures were obtained from blood, urine, tracheo-bronchial
secretions, and from any other site with a clinical suspicion of
infection. Bacteria were cultured using standard microbiological
methods. Antimicrobial susceptibility testing was performed using
the automated BD Phoenix system (USA) and the Kirby–Bauer disk
diffusion technique (Clinical Laboratory Standards Institute,
CLSI).11 Antimicrobial treatment was considered appropriate when
the patient received an antibiotic to which the isolated bacteria
were susceptible, during the ﬁrst 24 h of clinical infection, and if
the patient received this for 72 h.12
Infections occurring at more than one site in the same patient
were reported as separate infection events, unless the same
bacterium was isolated at the same time. The clinical outcome was
assessed until hospital discharge or death. For the purposes of this
investigation, death was classiﬁed as attributed to the HAI or as
non-HAI infection-related according to the medical professional
who certiﬁed the death, along with a clinical chart review by at
least two of the authors of the current article.
MDRB included the following: methicillin-resistant Staphylo-
coccus aureus (MRSA), vancomycin-resistant Enterococcus faecium
(VRE), and extended-spectrum beta-lactamase (ESBL)-producingTable 1
Hospital-acquired infections (HAI), overall mortality, and infection-related
mortality in an intensive care unit (ICU)
Year 2007 2008 2009 2010 2011
HAI rate 8.6 8.9 11.5 9.5 17.4
Patients admitted to the ICU (n) 341 296 277 273 252
ICU overall mortality (%) 19 18 17 18 18
HAI mortality (%) 19 31 29 25 53
ICU stay, days, median (IQR) 4 (2–4) 2 (1–4) 2 (1–6) 3 (1–6) 4 (2–5)
Infection rate by site
VAP 3.8 4.7 4.3 3.7 9.5
VAP/1000 ventilator-days 11.7 15.8 14.4 12.2 31.7
CA-UTI 2 3 3.9 3.7 2.6
CA-UTI/1000 catheter-day 3.4 5 6.6 6.1 3.6
CLABSI 0.8 0 0.4 0 0.8
SSI 0.3 1.3 1.8 1 2.1
Abdominal sepsis 0.6 1 1.1 2.2 2
Prevalence (%) MDR-HAI
pathogensa
37.5 33.3 29.4 33.3 65.1
IQR, interquartile range; VAP, ventilator-associated pneumonia; CA-UTI, catheter-
associated urinary tract infection; CLABSI, central line-associated bloodstream
infection; SSI, surgical site infection; ESBL, extended-spectrum beta-lactamase;
XDR, extensively drug-resistant; MRSA, methicillin-resistant Staphylococcus aureus;
VRE, vancomycin-resistant Enterococcus.
a MDR, multidrug-resistant bacteria (ESBL Escherichia coli, MDR/XDR Pseudomo-
nas aeruginosa, MDR Acinetobacter baumannii, MRSA, VRE).Escherichia coli and Klebsiella spp. Pseudomonas aeruginosa,
Acinetobacter spp, and other Gram-negative bacteria were consid-
ered multidrug-resistant (MDR) if they showed resistance to
ﬂuoroquinolones, cephalosporins, and carbapenems.
2.1. Statistical analysis
Categorical variables were compared using the Chi-square test
or Fisher’s exact test, as appropriate. Continuous data were
compared by means of the Mann–Whitney U-test or the Student t-
test according to the data distribution. Odds ratios (OR) with 95%
conﬁdence intervals (95% CI) were calculated. p-Values of 0.05
were considered statistically signiﬁcant. Device utilization ratios,
site-speciﬁc incidence rates per 100 patients, and site-speciﬁc
incidence densities per 1000 days at risk or per 1000 patient-days
were calculated. Data were analyzed using Epi-Info (v. 7) and
STATA (v. 12) statistical software.
3. Results
During the study period there were 1418 admissions to the ICU.
There were 159 HAI in 134 patients (110 with one, 23 with two,
and one with three HAI episodes). The overall incidence of HAI in
the ICU was 11.2 per 100 patients and 32.2/1000 patient-days
(Table 1).
The median patient age was 50 years; 65 patients (48.4%) were
male. The most frequent causes of ICU admission were septic shock
(43%), hypovolemic shock (25%), respiratory failure (15%), and
postoperative care (10%). Other demographic and clinical char-
acteristics are shown in Table 2.
Seventy-two patients (45.3%) had ventilator-associated pneu-
monia (VAP), 41 (25.8%) had a catheter-associated urinary tractGenitourinary 32 (23.9)
Lymphoma 16 (11.9)
Acute leukemia 14 (10.4)
Esophagus and stomach 10 (7.5)
Colon and rectum 9 (6.7)
Breast 6 (4.5)
Status of cancer at ICU admission
Recent diagnosis 83 (64)
Progression 11 (8.5)
Complete remission 16 (12.3)
Recurrence 12 (9.2)
Non-response 8 (6.1)
ICU admission diagnosis
Septic shock 58 (43)
Hypovolemic shock 33 (25)
Respiratory failure 20 (14.9)
Postoperative surgical care 14 (10.4)
Other reasons 6 (4.4)
Chemotherapy within 2 months 26 (19.4)
Mechanical ventilation 131 (97.8)
Comorbidities
No comorbidities 97 (72.4)
Hypertensiona 17 (12.7)
Diabetes mellitus 14 (10.4)
Chronic renal failure 6 (4.5)
Otherb 7 (5.2)
a Six patients had two co-morbidities.
b Four patients with systemic lupus erythematosus, one with
fever and neutropenia, one with HIV, and one with deep venous
thrombosis.
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(12.6%) were cases of abdominal sepsis, and ﬁve (3.1%) had a
central line-associated bloodstream infection (CLABSI).
The CA-UTI rate was 17.1/1000 catheter-days. The mean VAP
rate was 8.2/1000 ventilator-days. The mean number of days of
mechanical ventilation in the patients who developed VAP was
14.4  10.2 days.
Of all nosocomial infections, 145 (91.2%) were culture-
conﬁrmed and 14 (8.8%) were clinically deﬁned as culture-
negative infections. There were 266 microorganisms isolated, of
which 105 were considered MDR; the overall prevalence was
39.5%. These bacteria were distributed as follows: 148 Gram-
negative (55.6%), 86 Gram-positive (32.3%), and 32 yeasts (12.1%).
The most frequent organisms were E. coli (n = 54, 20%; 94.4% of
these were ESBL producers), S. aureus (n = 32, 12%; 90.6% of these
were MRSA), E. faecium (n = 32, 12%; 18.7% were VRE), P. aeruginosa
(n = 29, 11%; 14% were MDR), and Acinetobacter baumannii (n = 15,
6%; all MDR) (Table 3).
The mean number of days of ICU hospitalization was greater in
patients who developed MDRB-HAI compared to patients with HAI
with susceptible bacteria (16  10 vs. 12  6 days, p = 0.02). MDRB
were most frequently isolated in patients who developed VAP (p = 0.03)
and bacteremia (p = 0.003). Appropriate empirical antimicrobial
treatment was initiated in 75 patients (56%), although it did not
inﬂuence mortality (p = 0.9), even in the presence of MDRB (p = 0.8).
The SOFA score at ICU admission was 8.4  3.3, and at HAI
diagnosis was 7.4  4.1 (p = 0.03), with no statistical difference
between patients who developed and those who did not develop
MDRB-HAI (7.1  3.5 vs. 7.4  4.1, respectively p = 0.5).
The mortality rate of patients with hematological malignancies
did not differ from that of patients with solid tumors, even in those
with MDRB (p = 0.7).
Among patients admitted to the ICU (n = 1418) during the study
period, 252 died (17.8%). Fifty-eight patients (23%) had an HAI, and 51
(88%) of these had an MDRB isolated. The mortality related to MDRB-
HAI was signiﬁcantly higher than that for non-MDRB-HAI (p = 0.05).
In 2011, the ICU experienced a 5-month outbreak of MDR
A. baumannii, isolated from bronchial secretions of 13 patientsTable 3
Most frequent microorganisms isolated in intensive care unit (ICU) patients with hosp
Microorganisms Pneumonia Urinary tract infection Surgica
Escherichia coli
ESBL 10 7 10 
Non-ESBL 4 4 0 
Staphylococcus aureus
MRSA 13 0 7 
MSSA 1 0 0 
Enterococcus faecium
VRE 0 1 2 
Vancomycin-sensitive 3 9 4 
Other Gram-negativea 16 5 11 
Pseudomonas aeruginosab
MDR 2 0 0 
XDR 3 0 0 
Non-resistant 15 5 3 
Acinetobacter baumanniic
MDR 12 1 2 
Enterococcus faecalisd 3 6 8 
Klebsiella sppd 8 2 0 
Total
MDR 40 9 21 
Non-MDR 50 31 26 
ESBL, extended-spectrum beta-lactamase; MRSA, methicillin-resistant Staphylococcus au
Enterococcus;
a Other Gram-negative: Enterobacter cloacae, Enterobacter aerogenes, Morganella
mirabilis, Stenotrophomonas maltophilia, Acinetobacter lwofﬁi.
b MDR, multidrug-resistant (resistant to ﬂuoroquinolones and cephalosporins); XDR
c All A. baumannii strains were MDR (except for tigecycline and colistin). All were is
d These bacteria were not MDR.(also isolated from blood in one patient, urine and surgical site
infection in one patient each); in two patients it was isolated only
in blood cultures. Eleven patients died (73%) increasing the HAI
mortality to 53%.
4. Discussion
Cancer is a leading cause of death worldwide, accounting for
13% of all deaths in the year 2008.13 Along with its higher
incidence, more cancer patients receive multimodal treatment,
with chemotherapy, radiation therapy, surgery, and/or molecular
targeted therapies, with increased rates of remission and cure.
Within in-hospital medical care, patients with cancer admitted to
the ICU are becoming more common.14–17
ICU-HAI rates are higher than in general hospital wards due to
the complex interactions between the patient’s underlying
diseases, comorbidities, severity of illness, type of ICU, length of
stay, and use of multiple invasive devices.2,18 A study conducted in
patients with hematological malignancies admitted to the ICU
showed that mechanical ventilation and the failure of two or more
organs were independently associated with in-hospital mortality.
Mortality reported in the ICU, in-hospital, and at 6 months were
34%, 46%, and 59%, respectively.15 Another study reported that
mortality in cancer patients was negatively inﬂuenced by
respiratory failure and the development of septic shock during
the ICU stay.16
A previous study at our institution showed an overall mortality
over a 6-year surveillance period of 18% (302 deaths/1670
patients), but there were no data on the related infections.8 In
this study, mortality was reported in 18%; 23% of all cases were
associated with an HAI.
Analyzing the infection rate by site, there was a clear increase in
VAP in 2011 related to the Acinetobacter outbreak described
above. The prevalence of MDR-HAI pathogens was signiﬁcantly
higher in the same year. Analyzing the remainder of the study
period (2007–2010), there was no signiﬁcant variation in the
infection rate. Of note, the CLABSI rate remained less than 1, whichital-acquired infections (HAI) (2007–2011)
l site infection Bloodstream infection Abdominal sepsis Total
11 4 42
3 1 12
9 0 29
1 1 3
3 0 6
9 1 26
3 1 31
2 0 4
1 0 4
5 1 29
5 0 20
3 0 20
1 0 11
31 4 105
25 5 137
reus. MSSA, methicillin-sensitive Staphylococcus aureus; VRE, vancomycin-resistant
 morganii, Serratia marcescens, Klebsiella oxytoca, Citrobacter freundii, Proteus
, extensively drug-resistant (also resistant to carbapenems).
olated in 2011 corresponding to an ICU outbreak.
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hospital.
The risk of infection with MDRB has been related to a number of
factors, including previous antimicrobial therapy, cross-transmis-
sion, and length of hospital stay.3,19 Critically ill cancer patients
admitted to the ICU have a major risk of MDRB-HAI infection that
will impact negatively on mortality,2,20 rendering the enormous
efforts to cure and control the cancer wasteful and inefﬁcient.
Eighty-eight percent of our patients who developed an HAI and
died had an MDRB isolated, reﬂecting the relationship between
these multi-resistant bacteria and the high risk of mortality.
As previously reported, the increase in mortality among
patients with MDRB-HAI, even with appropriate therapy, is higher
compared to increases in other series of non-cancer patients.20 In
agreement with other studies, we found a higher mortality in
patients with MDRB-HAI, regardless of whether or not they had
received appropriate antimicrobial therapy. These ﬁndings may be
explained by the morbidity and organ failure present in ICU
patients acting as independent factors related to mortality. In a
previous report from our institution involving patients with
hematological malignancies and bacteremia due to ESBL E. coli,
mortality was twice that of patients with non-ESBL E. coli
isolated.12 The percentage of isolates observed to have antimicro-
bial resistance in our ICU reﬂects the common and increasing
problem of emerging resistance patterns in all types of hospital
wards.21
In 2011, the HAI rate and HAI mortality increased in relation to
an MDR-Acinetobacter spp outbreak. This bacterium has become an
emerging nosocomial pathogen, particularly in the ICU setting, and
is frequently associated with outbreaks, most commonly of VAP.22–
24 It has often been attributed to contaminated medical equipment
and materials in contact with water, as well as environmental
surfaces.19,25 When other resistant microorganisms were evaluat-
ed, none was associated with a high mortality or longer duration of
hospitalization, although estimates are imprecise given the low
number of these latter isolates.
Our institutional program enhances antimicrobial stewardship
and monitors antimicrobial resistance. These measures have been
reinforced since 2011, including ICU antimicrobial restriction and
consultation with an infectious diseases specialist, de-escalation of
therapy, and antimicrobial dose optimization.
The emergence of MDRB poses a difﬁcult task for physicians,
who have access to limited or non-existent therapeutic options.
Critically ill cancer patients admitted to the ICU are at major risk of
MDRB-HAI that will impact adversely on mortality, despite
enormous efforts and expense.
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